JOURNAL OF DRUG ISSUES JCR impact factor overview
This profile summarizes the journal metrics and publication information available in the current directory record.
JOURNAL OF DRUG ISSUES metric snapshot
JOURNAL OF DRUG ISSUES has a bibliometric profile in this directory for 2025. The publisher recorded for the journal is SAGE PUBLICATIONS INC. Its listed Clarivate Journal Citation Reports (JCR)-based Journal Impact Factor is 1.200. The five-year Journal Impact Factor is 1.400, giving a second citation window for comparison. The journal is recorded in quartile Q4 for its listed JCR category.
Category position and quartile
The recorded JCR category position is 45 out of 58 journals. Based on that rank position, the journal sits within approximately the top 78% of the listed category. Its listed quartile is Q4. Category ranks and quartiles are field-specific and are not measures of the quality of an individual article.
How the citation indicators compare
The five-year Journal Impact Factor (1.400) is 0.200 points higher than the standard Journal Impact Factor (1.200). The Impact Factor without journal self-citations is the same as the listed standard value at the displayed precision. The Journal Citation Indicator (JCI) is recorded as 0.460. These measures use different definitions or citation windows, so they are most useful when read together rather than treated as interchangeable scores.
Citation and publication counts
For 2025, the directory record for JOURNAL OF DRUG ISSUES lists total cites: 1,184; total articles: 49; citable items: 49. These fields describe different parts of the JCR record and should not be combined into an article-level quality score.
Citation half-life profile
The cited half-life is 11.7 years, indicating the median age of items that contributed citations to the journal in the reporting framework. The citing half-life is 7.4 years, indicating the median age of references used by the journal’s articles.
Identifiers and verification
JOURNAL OF DRUG ISSUES is identified in this directory by print ISSN 0022-0426 and electronic ISSN 1945-1369. The publisher is recorded as SAGE PUBLICATIONS INC. When making submission, library, or research-evaluation decisions, verify the title and identifiers against the journal publisher and the official Clarivate Journal Citation Reports record.
Complete journal information
Use this table to verify the individual metric values, identifiers and publication details stored for this journal.
| Journal name | JOURNAL OF DRUG ISSUES |
|---|---|
| Abbreviated journal | J DRUG ISSUES |
| Publisher | SAGE PUBLICATIONS INC |
| Metric year | 2025 |
| Overall rank | 12,283 |
| ISSN | 0022-0426 |
| eISSN | 1945-1369 |
| Total cites | 1,184 |
| Total articles | 49 |
| Citable items | 49 |
| Cited half-life | 11.7 years |
| Citing half-life | 7.4 years |
| JCR-based Journal Impact Factor | 1.200 |
| 5-Year Impact Factor | 1.400 |
| Impact Factor without journal self-cites | 1.200 |
| Journal Citation Indicator | 0.460 |
| JCR Impact Factor quartile | Q4 |
| JCR category rank | 45/58 |
| Database record updated |
Frequently asked questions
What is the 2025 JCR-based Journal Impact Factor of JOURNAL OF DRUG ISSUES?
The Journal Impact Factor recorded in this directory as a Clarivate Journal Citation Reports (JCR)-based value for JOURNAL OF DRUG ISSUES is 1.200 for the 2025 metric year.
What are the JCR quartile and category rank of JOURNAL OF DRUG ISSUES?
JOURNAL OF DRUG ISSUES is listed with quartile Q4 and category rank 45/58. These values are category-specific and should be verified against the official JCR record when used for formal assessment.
What is the five-year Journal Impact Factor of JOURNAL OF DRUG ISSUES?
The five-year Journal Impact Factor recorded for JOURNAL OF DRUG ISSUES is 1.400. It uses a longer citation window than the standard Journal Impact Factor.
Who publishes JOURNAL OF DRUG ISSUES?
JOURNAL OF DRUG ISSUES is listed in this directory as being published by SAGE PUBLICATIONS INC.
Related journal profiles
Additional records from the same publisher or with a similar listed JCR Impact Factor.